NNC0487-0111 for Obesity and Osteoarthritis

(AMAZE 5 Trial)

This trial aims to determine if a new treatment, NNC0487-0111, is safe and effective for individuals with excess body weight and knee osteoarthritis. Participants will receive weekly injections of either the new treatment or a placebo (a substance without active medicine). The trial targets those who have experienced knee pain for over 90 days and have felt pain in their knee on most days in the past month. As a Phase 3 trial, it represents the final step before FDA approval, providing participants an opportunity to contribute to the development of a potentially groundbreaking treatment.

The trial requires a 72-hour period without taking pain relievers (analgesics) before certain visits, but you can use acetaminophen as needed up to 24 hours before those visits. Other medications are not specifically mentioned, so it's best to discuss with the trial team.

Previous studies have shown that NNC0487-0111 is well-tolerated by patients. Participants experienced significant weight loss, and the treatment was generally easy to handle. Some side effects occurred, but they were mostly mild. These findings suggest that NNC0487-0111 is relatively safe for humans. However, like any treatment, it may carry risks, so discussing any concerns with the study team is important.¹²³⁴⁵

Unlike the standard treatments for obesity and osteoarthritis, which often involve lifestyle changes, medications like orlistat, or surgical interventions, NNC0487-0111 offers a novel approach by being administered subcutaneously once a week. Researchers are excited about it because it potentially integrates seamlessly into a patient's routine while supporting a reduced-calorie diet and increased physical activity. The dual-dose levels being tested could allow for personalized treatment plans, optimizing effectiveness and minimizing side effects. This innovative delivery method and potential customization set NNC0487-0111 apart from existing options.

Research shows that NNC0487-0111 may aid in weight loss. In this trial, participants will receive either NNC0487-0111 at varying doses or a placebo, alongside a reduced-calorie diet and increased physical activity. Clinical trials have found that treatments like cagrilintide, used alone or with semaglutide, can lead to significant weight loss, with some studies showing participants losing up to 22% of their body weight. Although the impact on knee osteoarthritis remains under investigation, early results suggest this treatment might also help reduce joint pain. Overall, NNC0487-0111 appears to be a promising option for treating obesity and potentially easing knee pain from osteoarthritis.¹³⁶⁷⁸